CPL-409116 is under clinical development by Celon Pharma and currently in Phase II for Rheumatoid Arthritis. According to GlobalData, Phase II drugs for Rheumatoid Arthritis have a 32% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CPL-409116’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CPL-409116 overview

CPL-409116 is under development for the treatment of idiopathic pulmonary fibrosis, pulmonary arterial hypertension, rheumatoid arthritis, plaque psoriasis and cytokine release storm in Covid-19. The drug candidate contained in the tablet called PG242 (60 mg). It is administered through oral route. The drug candidate acts by inhibiting Janus kinase1 (JAK1), Janus kinase3 (JAK3) and rho-kinases.

Celon Pharma overview

Celon Pharma a subsidiary of Glatton Sp Zoo, is a biopharmaceutical company that researches, develops, produces and distributes generic medicinal products and pharmaceutical preparations to treat cancer, diabetes, neurological and metabolic diseases. The company’s product range includes Aromek, Salmex, Valzek, Lazivir, Donepex and Ketrel. It is investigating drugs against solid tumors, neuropathic pain, asthma, autoimmune diseases, diabetes, psoriasis, Schizophrenia and drug-resistant depression among others. Celon Pharma conducts advanced scientific research and development programs to produce modern drugs. The company works in collaboration with academic and research institutions to discover new therapies. Celon Pharma is headquartered in Lomianki, Mazovia, Poland.

For a complete picture of CPL-409116’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.